PE20040925A1 - DERIVADOS DE PIRAZOL COMO INHIBIDORES DEL FACTOR Xa - Google Patents

DERIVADOS DE PIRAZOL COMO INHIBIDORES DEL FACTOR Xa

Info

Publication number
PE20040925A1
PE20040925A1 PE2004000015A PE2004000015A PE20040925A1 PE 20040925 A1 PE20040925 A1 PE 20040925A1 PE 2004000015 A PE2004000015 A PE 2004000015A PE 2004000015 A PE2004000015 A PE 2004000015A PE 20040925 A1 PE20040925 A1 PE 20040925A1
Authority
PE
Peru
Prior art keywords
members
thiofen
mono
alkylene
compounds
Prior art date
Application number
PE2004000015A
Other languages
English (en)
Inventor
Marc Nazare
Wolkmar Wehner
David William Will
Hans Matter
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02028915A external-priority patent/EP1433788A1/en
Priority claimed from EP03011308A external-priority patent/EP1479678A1/en
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20040925A1 publication Critical patent/PE20040925A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I, DONDE R0 ES UN HETEROCICLILO MONO O BICICLICO DE 4 A 15 MIEMBROS QUE CONTIENE DE 1 A 4 HETEROATOMOS DE N, S Y O, OPCIONALMENTE SUSTITUIDO; UN HETEROCICLILO SELECCIONADO DE BENZOIMIDAZOLILO, 1,3-BENZODIOXOLILO, BENZOFURANILO, BENZOXAZOLILO, ENTRE OTROS, UN ARILO MONO O BICICLICO DE 6 A 14 MIEMBROS, OPCIONALMENTE SUSTITUIDO POR R8; Q ES UN ENLACE DIRECTO, -ALQUILENO(C0-C2)-C(O)-NR10-, -NR10-C(O)-NR10-, -NR10-C(O)-, -SO2-, ENTRE OTROS; R1 ES H, ALQUILO(C1-C4), ALQUILENO(C1-C3)-C(O)-NH-R0, ENTRE OTROS; R2 ES UN ENLACE DIRECTO O ALQUILENO (C1-C4), O R1 Y R3 JUNTOS FORMARIAN UN GRUPO CICLICO DE 6 A 8 MIEMBROS CON 1 A 4 HETEROATOMOS DE N, S Y O; V ES UN RESTO CICLICO DE 3 A 7 MIEMBROS, ARILO DE 6 A 14 MIEMBROS O HETEROCICLILO MONO O BICICLICO DE 4 A 15 MIEMBROS OPCIONALMENTE SUSTITUIDO POR R14; G ES UN ENLACE DIRECTO, -(CH2)m-NR10-SO2-NR10-(CH2)n-, -(CH2)m-CH(OH)-(CH2)n, -(CH2)m, ENTRE OTROS; M ES H, -ALQUILO(C1-C8), -C(O)-N(R11)-R12-, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (1-ISOPROPIL-PIPERIDIN-4-IL)-AMIDA DEL ACIDO 2-[5-(5-CLORO-TIOFEN-2-IL)-ISOXAZOL-3-ILMETIL]-5-TIOFEN-2-IL-2H-PIRAZOL-3-CARBOXILICO, (1-ISOPROPIL-PIPERIDIN-4-IL)-AMIDA DEL ACIDO 1-[5-(5-CLORO-TIOFEN-2-IL)-ISOXAZOL-3-ILMETIL]-5-TIOFEN-2-IL-1H-PIRAZOL-3-CARBOXILICO, ENTRE OTROS. ESTOS COMPUESTOS SON INHIBIDORESS REVERSIBLES DE LAS ENZIMAS DE COAGULACION SANGUINEA FACTOR Xa(FXa) Y/O FACTOR VIIa Y SON ADECUADOS PARAEL TRATAMIENTO DE ENFERMEDADES TROMBOEMBOLICAS Y REESTENOSIS
PE2004000015A 2002-12-23 2004-01-05 DERIVADOS DE PIRAZOL COMO INHIBIDORES DEL FACTOR Xa PE20040925A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02028915A EP1433788A1 (en) 2002-12-23 2002-12-23 Pyrazole-derivatives as factor Xa inhibitors
EP03011308A EP1479678A1 (en) 2003-05-19 2003-05-19 Pyrazole-derivatives as factor xa inhibitors

Publications (1)

Publication Number Publication Date
PE20040925A1 true PE20040925A1 (es) 2004-12-24

Family

ID=32683809

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000015A PE20040925A1 (es) 2002-12-23 2004-01-05 DERIVADOS DE PIRAZOL COMO INHIBIDORES DEL FACTOR Xa

Country Status (13)

Country Link
EP (1) EP1581523B1 (es)
JP (1) JP4585448B2 (es)
AR (1) AR042648A1 (es)
AT (1) ATE444292T1 (es)
AU (1) AU2003292218A1 (es)
BR (1) BR0317659A (es)
CA (1) CA2511321A1 (es)
DE (1) DE60329529D1 (es)
IL (1) IL169323A0 (es)
MX (1) MXPA05006200A (es)
PE (1) PE20040925A1 (es)
TW (1) TW200505914A (es)
WO (1) WO2004056815A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
DE102004047255A1 (de) * 2004-09-29 2006-04-13 Merck Patent Gmbh Prolinderivate
WO2006047415A2 (en) 2004-10-26 2006-05-04 Janssen Pharmaceutica, N.V. Factor xa compounds
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
WO2006050034A1 (en) * 2004-10-29 2006-05-11 Schering Corporation Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
EP1724269A1 (en) * 2005-05-20 2006-11-22 Sanofi-Aventis Deutschland GmbH Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
WO2007002563A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
EP1968579A1 (en) 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
US8435970B2 (en) 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
EP2238127B1 (en) * 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) * 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
EP2264017A4 (en) 2008-04-04 2011-07-27 Takeda Pharmaceutical Heterocyclic derivative and its use
JP5658138B2 (ja) * 2008-04-23 2015-01-21 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害の処置のためのカルボキサミド化合物
AR079967A1 (es) 2010-01-26 2012-02-29 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos
CN104940200B (zh) 2010-03-30 2019-06-28 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
TWI523844B (zh) 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
UY33874A (es) 2011-01-26 2012-08-31 Sanofi Aventis Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas
CA2841905A1 (en) 2011-07-26 2013-01-31 Sanofi 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
BR112014001587A2 (pt) 2011-07-26 2017-02-14 Sanofi Sa derivados de ácido 3-(tiazol-4-carbonil)- ou 3-(tiazol-2-carbonil) amino-propiônico substituídos e seu uso como produtos farmacêuticos
US20130123325A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
CN105209440B (zh) 2013-03-15 2019-07-23 维颂公司 作为凝血酶抑制剂的卤代吡唑
SG10201707480PA (en) * 2013-03-15 2017-10-30 Verseon Corp Multisubstituted aromatic compounds as serine protease inhibitors
CN105073720B (zh) 2013-03-28 2017-10-13 赛诺菲 联芳基‑丙酸衍生物及其作为药物的用途
AU2014243069B2 (en) 2013-03-28 2017-12-21 Sanofi Biaryl-propionic acid derivatives and their use as pharmaceuticals
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
CN106687445A (zh) 2014-09-17 2017-05-17 维颂公司 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物
DK3261639T3 (da) 2015-02-27 2022-10-31 Verseon Int Corporation Substituerede pyrazolforbindelser som serinproteaseinhibitorer
WO2016202756A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
JOP20190192A1 (ar) * 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
EP1045846B1 (en) * 1997-11-28 2003-05-02 Lg Chemical Limited Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
JP2001526268A (ja) * 1997-12-22 2001-12-18 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤としての、オルト−置換Ｐ１を有する、窒素含有複素環式芳香族化合物
CN100340559C (zh) * 1998-12-23 2007-10-03 布里斯托尔-迈尔斯斯奎布药品公司 作为凝血因子xa抑制剂的含氮杂双环
BR0013200A (pt) * 1999-07-16 2002-05-07 Bristol Myers Squibb Pharma Co Compostos derivados de heterobiciclos contendo nitrogênio, composições farmacêuticas, método de tratamento ou prevenção de uma disfunção tromboembólica e uso dos compostos
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CN1390206A (zh) * 1999-09-17 2003-01-08 千嬉药品公司 因子Xa的抑制剂
EP1226123A1 (en) * 1999-11-03 2002-07-31 Du Pont Pharmaceuticals Company Cyano compounds as factor xa inhibitors
WO2002000647A1 (en) * 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
WO2002085356A1 (en) * 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1, 4, 5, 6-tetrahydropyrazolo-[3, 4-c]-pyrid in-7-ones as factor xa inhibitors

Also Published As

Publication number Publication date
WO2004056815A1 (en) 2004-07-08
JP2006511608A (ja) 2006-04-06
AU2003292218A1 (en) 2004-07-14
MXPA05006200A (es) 2005-08-19
IL169323A0 (en) 2007-07-04
JP4585448B2 (ja) 2010-11-24
ATE444292T1 (de) 2009-10-15
AR042648A1 (es) 2005-06-29
BR0317659A (pt) 2005-12-06
DE60329529D1 (de) 2009-11-12
TW200505914A (en) 2005-02-16
EP1581523B1 (en) 2009-09-30
EP1581523A1 (en) 2005-10-05
CA2511321A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
PE20040925A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DEL FACTOR Xa
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
PE20041016A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
PE20050489A1 (es) Antagonistas de receptores de acetilcolina muscarinicos
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20061096A1 (es) Derivados de oxiindol como agonistas 5-ht4
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
PE20081238A1 (es) Piperidinas sustituidas como antagonistas de hdm2
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
DOP2002000334A (es) Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
EA200100457A1 (ru) Способ получения циталопрама
PE20030593A1 (es) DERIVADOS DE INDOL COMO INHIBIDORES DEL FACTOR Xa
PE20011314A1 (es) DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA COMO INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
PE20081135A1 (es) Derivados que contienen sulfamoilo y sus usos
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
PE20040598A1 (es) Tetrahidropiranil-ciclopentil-tetrahidropiridopiridinicos como moduladores de la actividad de receptores de quimiocina
PE20060483A1 (es) Compuestos heterociclicos como antagonistas de nk1
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20040666A1 (es) Derivados novedosos de piperidina

Legal Events

Date Code Title Description
FD Application declared void or lapsed